翰森制药集团有限公司 (香港) (中国香港特别行政区)

The Company is a China-based investment holding was incorporated in the Cayman Islands under the Companies Law as an exempted company with limited liability on 2 December 2015. On 14 June 2019, the Company has listed at MAIN Board of Hong Kong Stock Exchange.
The Company and its subsidiaries are principally engaged in the research and development, production and sale of pharmaceutical products in China. The Company's main products include Oulanning, Ameining, Pulaile, Zefei, Xinwei, Xinmei, Zetan, Mailingda, Hengjie, Hengsen, Fulaidi and Ruibote, among others. The Company's products are mainly used for central nervous system disease, oncology, anti-infection, diabetes, digestive tract and cardiovascular treatment. The Company distributes its products in domestic market. The company has over 20 years of R D experience, as evidenced by top-two ranking as of June 30, 2018 in both the number of Category 1.1 innovative drug candidates with IND approval and the number of first-to-market generic drug approvals since 2011. The company has began development of Category 1.1 innovative drugs in 2002. They have become Chinese pharmaceutical companies that have successfully developed and marketed two Category 1.1 innovative drugs with NMEs, including pipeline Category 1.1 innovative drug polyethylene glycol loxenatide, launched in May 2019.
MILESTONES :

1995 - Jiangsu Hansoh as major operating subsidiary was established in China.
2000 - First GMP manufacturing facility in Lianyungang, Jiangsu Province is launched and commenced production of solid oral formulations.
2002 - The company were recognized as a Key High and New-Technology Enterprise of the National Torch Program. The company obtained Chinese GMP certifications for our production of large volume parenteral solutions.
2003 - Active pharmaceutical ingredient, vinorelbine tartrate, was approved by the U.S. FDA.
2006 - The company was received approval to establish a Postdoctoral Program Workstation by the Ministry of Personnel and the National Postdoctoral Management Committee of China.
2008 - The company was certified as a National Enterprise Technology Center.
2014 - Self-developed Category 1.1 innovative drug Mailingda (morinidazole sodium chlorider injection), the latest generation nitroimidazole-class antibiotic, was approved for sale in China.
2015 - core product, Zefei (gemcitabine hydrochloride for injection), was recognized as a Famous China Trademark y the Trademark Office of the State Administration for Industry Commerce of China.
2016 - Hillhouse was brought in as investor. core product, Oulanning (olanzapine tablets), received the China Patent Excellence Award from the State Intellectual Property Office of China. core product, Xinwei (imatinib mesylate tablets), received the first prize for the
Advancement of Science and Technology by the All-China Federation of Industry Commerce. core product, Pulaile (pemetrexed disodium for injection), was approved by the PMDA.